Brief: Amylyx Pharmaceuticals Says FDA Granted Voluntary Request To Withdraw Approval Of Relyvrio
28/08/2025 18:42
Aug 28 (Reuters) - Amylyx Pharmaceuticals Inc AMLX.O: AMYLYX PHARMACEUTICALS- SUBMITTED VOLUNTARY REQUEST TO WITHDRAW APPROVAL OF RELYVRIO FOR TREATMENT OF ALS, FDA GRANTED REQUEST Further company coverage: AMLX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amylyx Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-LSI Industries, SiTime, Andersen Group
U.S. STOCKS ON THE MOVE-Apple, Hims & Hers Health, Sysco
U.S. STOCKS ON THE MOVE-Nordson, Nebius, Deere
Amylyx dips after increased $500 mln stock sale to fund blood sugar drug
Brief: Amylyx Pharmaceuticals Announces Pricing Of Upsized $500 Million Underwritten Public Offering Of Common Stock